influenza
vaccin
effect
prevent
influenza
viru
infect
associ
morbid
among
schoolag
children
potenti
temporari
nonspecif
immun
respiratori
virus
infect
consequ
interfer
popul
level
epidem
virus
hypothes
limit
empir
evid
date
mainli
ecolog
studi
investig
incid
acut
upper
respiratori
tract
infect
urti
associ
virolog
confirm
respiratori
viru
infect
random
control
trial
influenza
vaccin
doubleblind
random
control
trial
randomli
alloc
children
age
year
receiv
season
trival
influenza
inactiv
vaccin
tiv
ml
vaxigrip
sanofi
pasteur
placebo
serum
specimen
obtain
particip
vaccin
novemb
decemb
month
vaccin
midstudi
around
april
end
studi
august
octob
particip
follow
ill
symptom
diari
telephon
call
ill
report
household
member
trigger
home
visit
nasal
throat
swab
specimen
ntss
collect
household
member
defin
followup
period
particip
day
receipt
tiv
placebo
collect
midstudi
serum
sampl
winter
season
collect
midstudi
sampl
final
serum
sampl
obtain
summer
season
proxi
written
inform
consent
obtain
particip
parent
legal
guardian
addit
written
assent
year
age
studi
protocol
approv
institut
review
board
hong
kong
univers
ntss
test
respiratori
virus
resplex
ii
plu
multiplex
array
influenza
b
reversetranscript
polymeras
chain
reaction
rtpcr
supplementari
appendix
refer
infect
determin
assay
confirm
infect
inform
influenza
serolog
provid
supplementari
appendix
defin
acut
respiratori
ill
ari
determin
selfreport
sign
symptom
follow
sign
symptom
bodi
temperatur
headach
sore
throat
cough
presenc
phlegm
coryza
myalgia
defin
febril
acut
respiratori
ill
fari
bodi
temperatur
plu
cough
sore
throat
durat
followup
vari
particip
estim
incid
rate
ari
fari
episod
confirm
viral
infect
overal
winter
summer
season
estim
rel
risk
episod
particip
receiv
tiv
versu
placebo
use
incid
rate
ratio
use
poisson
regress
supplementari
appendix
statist
analys
conduct
use
r
version
r
develop
core
team
vienna
austria
data
syntax
reproduc
statist
analys
avail
correspond
author
web
site
among
particip
follow
median
durat
followup
day
interquartil
rang
day
statist
signific
differ
age
sex
household
size
durat
followup
tiv
placebo
recipi
tabl
identifi
ari
episod
met
stringent
fari
case
definit
ill
occur
throughout
studi
period
supplementari
appendix
figur
statist
signific
differ
risk
ari
fari
particip
receiv
tiv
receiv
placebo
either
winter
summer
tabl
abl
collect
ntss
test
particip
ari
episod
includ
fari
episod
mean
delay
ari
onset
collect
first
nt
day
ntss
collect
day
ill
onset
statist
signific
differ
tiv
placebo
recipi
detect
respiratori
virus
ntss
collect
ari
episod
includ
fari
episod
collect
ntss
particip
time
one
household
contact
report
acut
urti
particip
ill
identifi
virus
specimen
includ
influenza
coxsackieechoviru
coronaviru
statist
signific
differ
risk
confirm
season
influenza
infect
recipi
tiv
placebo
although
point
estim
consist
protect
tiv
recipi
rel
risk
rr
confid
interv
ci
tiv
recipi
significantli
lower
risk
season
influenza
infect
base
serolog
evid
supplementari
appendix
howev
particip
receiv
tiv
higher
risk
ari
associ
confirm
noninfluenza
respiratori
viru
infect
rr
ci
includ
addit
confirm
infect
particip
report
ari
tiv
recipi
higher
risk
confirm
noninfluenza
respiratori
viru
infect
rr
ci
major
noninfluenza
respiratori
viru
detect
rhinovirus
coxsackieechovirus
increas
risk
among
tiv
recipi
also
statist
signific
virus
tabl
prepandem
period
studi
observ
statist
signific
reduct
confirm
season
influenza
viru
infect
tiv
recipi
tabl
although
serolog
evid
supplementari
appendix
point
estim
vaccin
efficaci
base
confirm
infect
consist
protect
tiv
recipi
season
influenza
virus
circul
januari
march
identifi
statist
signific
increas
risk
noninfluenza
respiratori
viru
infect
among
tiv
recipi
tabl
includ
signific
increas
risk
rhinoviru
coxsackieechoviru
infect
frequent
detect
march
immedi
peak
season
influenza
activ
februari
figur
increas
risk
noninfluenza
respiratori
viru
infect
among
tiv
recipi
could
artefactu
find
exampl
measur
bia
could
result
particip
like
report
first
ari
episod
less
like
report
subsequ
episod
wherea
real
differ
rhinoviru
noninfluenza
respiratori
viru
infect
winter
influenza
season
increas
risk
could
also
indic
real
effect
receipt
tiv
could
increas
influenza
immun
expens
reduc
immun
noninfluenza
respiratori
virus
unknown
biolog
mechan
altern
result
could
explain
temporari
nonspecif
immun
influenza
viru
infect
cellmedi
respons
like
innat
immun
respons
infect
particip
receiv
tiv
would
protect
influenza
februari
would
heighten
nonspecif
immun
follow
week
would
face
higher
risk
certain
viru
infect
march
compar
placebo
recipi
figur
durat
temporari
nonspecif
immun
remain
uncertain
could
order
week
base
observ
less
like
interfer
observ
could
explain
reduc
commun
exposur
convalesc
ie
behavior
rather
immunolog
factor
phenomenon
viru
interfer
well
known
virolog
year
ecolog
studi
report
phenomena
potenti
explain
viral
interfer
nonspecif
immun
noninfluenza
respiratori
virus
report
children
week
receipt
live
attenu
influenza
vaccin
interfer
respiratori
gastrointestin
infect
report
receipt
live
oral
polioviru
vaccin
result
limit
small
sampl
size
small
number
confirm
infect
despit
limit
abl
observ
statist
signific
increas
risk
incid
rate
respiratori
specimen
collect
particip
age
year
receiv
trival
influenza
vaccin
placebo
acut
respiratori
ill
episod
abbrevi
ari
acut
respiratori
ill
ci
confid
interv
tiv
trival
inactiv
influenza
vaccin
incid
rate
estim
viru
detect
ill
episod
per
personyear
followup
ari
defin
least
follow
symptom
bodi
temperatur
cough
sore
throat
headach
runni
nose
phlegm
myalgia
b
tiv
recipi
detect
rhinoviru
coxsackieechoviru
detect
coxsackieechoviru
coronaviru
confirm
noninfluenza
respiratori
viru
infect
among
tiv
recipi
tabl
neg
associ
serolog
evid
influenza
infect
confirm
noninfluenza
viru
infect
winter
statist
signific
odd
ratio
ci
supplementari
appendix
one
must
cautiou
interpret
serolog
children
receiv
tiv
final
acut
urti
incid
base
selfreport
regular
telephon
remind
may
fail
identifi
ill
despit
rigor
prospect
followup
temporari
nonspecif
immun
lead
interfer
epidem
respiratori
virus
could
import
implic
first
observ
trial
tiv
appear
poor
efficaci
acut
urti
tabl
appar
protect
influenza
viru
infect
confer
tiv
offset
increas
risk
respiratori
viru
infect
tabl
second
interfer
respiratori
virus
could
suggest
new
approach
mitig
epidem
mass
administr
live
polio
vaccin
children
use
control
enteroviru
epidem
final
viral
interfer
could
bia
estim
influenza
vaccin
effect
testneg
casecontrol
studi
supplementari
appendix
one
testneg
studi
report
associ
receipt
tiv
risk
influenzalik
ill
associ
noninfluenza
viru
addit
work
requir
fulli
character
temporari
nonspecif
immun
overal
specif
group
children
anim
studi
volunt
adult
human
challeng
studi
could
provid
use
evid
addit
communitybas
observ
cohort
studi
communitybas
experiment
studi
vaccin
trial
may
particularli
suitabl
investig
temporari
nonspecif
immun
acut
urti
requir
medic
attent
supplementari
materi
avail
clinic
infecti
diseas
onlin
http
wwwoxfordjournalsorgourjournalscid
supplementari
materi
consist
data
provid
author
publish
benefit
reader
post
materi
copyedit
content
supplementari
data
sole
respons
author
question
messag
regard
error
address
author
financi
support
work
support
area
excel
scheme
hong
kong
univers
grant
committe
grant
number
hong
kong
univers
research
council
strateg
research
theme
public
health
harvard
center
communic
diseas
dynam
nation
institut
gener
medic
scienc
grant
number
research
fund
control
infecti
diseas
food
health
bureau
govern
hong
kong
sar
grant
number
fund
bodi
role
studi
design
data
collect
analysi
prepar
manuscript
decis
publish
